Tirilazad for aneurysmal subarachnoid haemorrhage

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Wang, L C ^b   Liu, Ming ^a   Wu, B ^b   Zhang, S H ^b  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TIRILAZAD;

BRAIN ARTERY ANEURYSM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; INJECTION SITE IRRITATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 44949098599     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006778     Document Type: Review

References (31)

1. Anderson 1988 Anderson DK, Braughler JM, Hall EK, Waters TR, McCall JM, Means ED. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. Journal of Neurosurgery 1988;69:562-7.
2. APT 1994 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
3. Biller 1988 Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1300-5.
4. Clarke 1997 Clarke HE, Kassell NFMD, Apperson-Hansen CM, Maile MHMS, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. Journal of Neurosurgery 1997;86:466-75.
5. Deitrich 2000 Deitrich HH, Dacey RG. Molecular keys to the problems of cerebral vasospasm. Neurosurgery 2000;46:517-30.
6. Fleishaker 1993a Fleishaker JC, Peters GR, Cathcart BS. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. I. Single-dose administration. Journal of Clinical Pharmacology 1993;33:175-81.
7. Fleishaker 1993b Fleishaker JC, Peters GR, Cathcart BS. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. Journal of Clinical Pharmacology 1993;33:182-90.
8. Fleishaker 1997 Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. International Journal of Clinical Pharmacology, Therapy and Toxicology 1997;35:28-32.
9. Grasso 2002 Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, et al.Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proceedings of the Academy of Natural Sciences of USA 2002;99:5627-31.
10. Hall 1988a Hall ED, Yonkers PA, McCall JM, Braughler JM. Effects of the 21-aminosteroid U74006F on experimental head injury inmice. Journal of Neurosurgery 1988;68:456-61.
11. Hall 1988b Hall D, Kay E, Pazara E, Braughler JM. 21-Aminosteroid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils. Stroke 1988;19(8):997-1003.
12. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library Issue 4, 2006. Chichester, UK: John Wiley & Sons Ltd, 2006.
13. Ho 1997 Ho HW, Batjer HH. Cerebrovascular Disease. Philadelphia: Lippincott-Raven Publishers, 1997.
14. ISAT 2002 Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al.International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002;360:1267-74.
15. Kanamaru 1990 Kanamaru K, Weir BKA, Findly JM, Grace M, MacDonald RL. A dosage study of the effect of the 21-aminosteroid U-74006F on chronic cerebral vasospasm in a primate model. Neurosurgery 1990;27:29-38.
16. Kanamaru 1991 Kanamaru K, Weir BKA, Simpson I, Witbeck T, Grace M. Effect of 21-aminosteroid U-74006F on lipid peroxidation in subarachnoid clot. Journal of Neurosurgery 1991;74:454-9.
17. Kassell 1985 Kassell NF, Sasaki T, Colohan ART, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985;16:562-72.
18. Kassell 1990 Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. Journal of Neurosurgery 1990;73:18-36.
19. Kassell 1996 Kassell NF, Clarke HE Jr, Apperson-Hansen C, Alves WM. Randomised, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal hemorrhage: a cooperative study in Europe, Australia, and New Zealand. Journal of Neurosurgery 1996;8:220-9.
20. Lanzino 1999a Lanzino G, Kassell NF, Dorsch NWC, Pasqualin A, Brandt L, Schmiedek P, et al.Double-blind, randomized, vehicle-controlled study of high-dose tirilazadmesylate in women with aneurysmal subarachnoid hemorrhage. Part 1. A cooperative study in Europe, Australia, New Zealand, and South Africa. Journal of Neurosurgery 1999;90:1011-7.
21. Lanzino 1999b Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. Journal of Neurosurgery 1999;90:1018-24.
22. Linn 1996 Linn FHH, Rinkel GJE, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year and rate of computed tomography: a meta-analysis. Stroke 1996;27:625-9.
23. Marshall 1998 Marshall LF, Maas AI, Marshall SB, Bricolo A, Fearnside M, Iannotti F, et al.A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. Journal of Neurosurgery 1998;89:519-25.
24. Matsui 1994 Matsui T, Kaizu H, Itoh S, Asano T. The role of active smooth muscle contraction in the occurrence of chronic vasospasm in the canine two-hemorrhage model. Journal of Neurosurgery 1994;80:276-82.
25. Meden 1996 Meden P, Overgaard K, Pedersen H, Boysen G. Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovascular Diseases 1996;6:141-8.
26. Schulz 1995 Schulz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
27. Steinke 1989 Steinke DE, Weir BKA, Findlay JM, Tanabe T, Grace M, Kruscheinycky BW. A trial of the 21-aminosteroid u-74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 1989;24:179-86.
28. TISC 2004 Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD002087. DOI:10.1002/14651858.CD002087.
29. Treggiari-Venzi 2001 Treggiari-Venzi MM, Suter PM, Roman J. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 2001;48:249-62.
30. Vollmer 1989 Vollmer DG, Kassell NF, Hongo K, Ogawa H, Tsukahara T. Effect of the non-glucocorticoid 21-aminosteroid lipid peroxidation inhibitor U-74006F on experimental cerebral vasospasm. Surgical Neurology 1989;31:190-4.
31. Zuccarello 1989 Zuccarello M, Marsch JT, Schmitt G, Woodward J, Anderson DK. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. Journal of Neurosurgery 1989;71:98-104.